With the acquisition of Weibel, SHL Medical looks to the development of novel drug delivery systems for self-administration, answering a need for improved patient-centricity in the sector.
Biohaven’s drug for acute treatment of migraine, manufactured using Catalent’s Zydis technology for orally disintegrating tablets, receives approval from the US FDA.
Abbott’s glucose sensing technology and a tubeless insulin delivery system developed by Insulet are set to create a personalized diabetes management solution.
Bioavailability of water insoluble compounds, such as CBD, enhanced up to 15 times with the technology of Solmic, leading to its acquisition by Betterlife.
Developers of generic drugs administered with topical drug delivery methods benefit from MedPharm’s in-vitro models to safely demonstrate bioequivalence.
Hikma taps Arestat, a formulation technology for protein- and peptide-based drugs, to develop an injectable medicine, ahead of filing for US FDA approval.
